Nagpur: The Food and Drug Administration (FDA) team on Tuesday seized a consignment of fairness cream up to Rs 33 lakh from 1 godown of M/s Saiyog Pharma Surgical Pvt Ltd in Wadi.
The action in the city was taken a day earlier after a similar operation by the Food and Drug Administration team in Thane. Where ‘Mayfair Cream’ worth about Rs 10 lakh was seized.
The Food and Drug Administration has lashed out at Zee Laboratories Ltd.’s 1 product ‘Mayfair Cream’ for violating the Drugs and Cosmetics Rules, 1945 and Schedule J. Which specifies a list of all those diseases or diseases which cannot be a medicine at all. And fully capable of treating or preventing including the fairness of skin.
Schedule J also lists about 51 types of conditions and diseases such as dementia, epileptic seizures, AIDS, impotence, increased brain function, the structure of breasts, size, shape, and hernia, goiter, the shape of male sex organ, and In the same way, even a single drug may not be able to cure or prevent at all. 1 Food and Drug Administration official has stated that any claim to cure or eliminate exactly the same diseases or conditions included in Schedule J is in violation of the law and is also liable to be acted upon.
‘Mayfair Cream’ seized from warehouse
Under the supervision of Joint Commissioner Viraj Paunikar in District Nagpur, Drug Inspector Maneesh Choudhari started action on it. And around 35-40 cartons of ‘Mayfair Cream’ were confiscated from the godown.
The Assistant Commissioner, Food and Drug Administration, PM Ballal has stated that the concerned fairness cream also contains Schedule H ingredients. Which should very strictly be sold under the prescription of registered medical practitioners. But in rural areas the product in the form of cosmetic cream was being picked up randomly from the shops by the school going students, which is not the case at all.
PM Ballal has stated that this manufacturer only advertises the product as 1 agent which can make 1 much better. This is misleading information and hence attracts penal provisions. Its sample will now be sent to the Food and Drug Administration headquarters in Mumbai for further processing.